Barzolvolimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Barzolvolimab
- barzolvolimab
- Barzolvolimab
- barzolvolimab [INN]
- BARZOLVOLIMAB [USAN]
- Barzolvolimab [WHO-DD]
- barzolvolimab inn
- barzolvolimab usan
- barzolvolimab who dd
- cdx 0159
- CDX-0159
- Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide with human-Mus musculus monoclonal CDX-0159 κ-chain, dimer
- immunoglobulin g1 233 alanine 234 glutamine 251 tyrosine 253 threonine 255 glutamic acid 321 glutamine de c terminal lysine anti human receptor tyrosine kinase kit extracellular domain human mus musculus monoclonal cdx 0159 γ1 chain disulfide with human mus musculus monoclonal cdx 0159 κ chain dimer
- immunoglobulin g1 kappa anti homo sapiens kit kit protooncogene receptor tyrosine kinase c kit c kit scfr cd117 extracellular domain monoclonal antibody gamma1 heavy chain 1 445 vh musmus homsap mus musculus ighv1 76 01 87 8 ighd ighj2 01 93 3 l124 v 112 homo sapiens ighv1 2 06 76 5 ighd ighj4 01 93 3 l123 t 111 cdr imgt 8 8 9 26 33 51 58 97 105 1 116 homo sapiens ighg1 01 g1m17 1 g1v21 ch2 y15 1 t16 e18 g1v20 ch2 a105 ch1 k120 213 117 214 hinge 1 15 215 229 ch2 l1 3 a 233 l1 2 q 234 m15 1 y 251 s16 t 253 t18 e 255 k105 q 321 230 339 ch3 d12 355 l14 357 340 444 chs k del 445 117 445 219 214 disulfide with kappa light chain 1 214 v kappa musmus homsap mus musculus igkv6 15 01 84 2 igkj1 01 90 9 l124 v 104 homo sapiens igkv1 16 01 81 1 igkj4 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 153 v101 191 108 214 dimer 225 225 228 228 bisdisulfide produced in chinese hamster ovary cho cells glycoform alfa
- immunoglobulin G1-kappa, anti-[Homo sapiens KIT (KIT protooncogene receptor tyrosine kinase, c-kit, c-Kit, SCFR, CD117) extracellular domain], monoclonal antibody; gamma1 heavy chain (1-445) [VH Musmus/Homsap (Mus musculus IGHV1-76*01 (87.8%) -(IGHD) -IGHJ2*01 (93.3%) L124>V (112)/Homo sapiens IGHV1-2*06 (76.5%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (111), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116) -Homo sapiens IGHG1*01, G1m17,1, G1v21 CH2 Y15.1, T16, E18, G1v20 CH2 A105 (CH1 K120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>A (233), L1.2>Q (234), M15.1>Y (251), S16>T (253), T18>E (255), K105>Q (321) (230-339), CH3 D12 (355), L14 (357) (340-444), CHS K>del (445)) (117-445)], (219-214')-disulfide with kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV6-15*01 (84.2%) - IGKJ1*01 (90.9%) L124>V (104)/Homo sapiens IGKV1-16*01 (81.1%) - IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') - Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'- 214')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
- CAS registry numbers
- 2438203-51-9
- ChEMBL ID
- CHEMBL5095266
- FDA ingredient codes (UNII)
- 4B77GX0NA3
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- barzolvolimab
- Type
- Antibody
- Drug name stem
- -mab
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- KIT proto-oncogene, receptor tyrosine kinase
- Gene symbol
- KIT
- Protein identifier
- P10721
- Condition
- Eosinophilic Esophagitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004232
- Subject identifier
- D057765
- Condition
- Chronic Urticaria
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0044212
- Subject identifier
- D000080223
- Condition identifier
- EFO_0004232
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005361
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006534
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007448
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0022799
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0026045
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0044212
- Highest recorded phase
- 3
- NCT04538794
- NCT05368285
- NCT06445023
- NCT06455202
- NCT05774184
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134''-194'' $ 143-199 $ 143''-199'' $ 219-214' $ 219''-214''' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGASVKLSCKASGYTFTDYYINWVRQAPGKGLEWIARIYPGSGNTYYNEKFKGRATLTADKSTSTAYMQLSSLRSEDTAVYFCARGVYYFDYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAQGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCQVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG
- Component
- Light chain
- Type
- Protein
- Sequence
- DIVMTQSPSSLSASVGDRVTITCKASQNVRTNVAWYQQKPGKAPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISSLQPEDFADYFCQQYNSYPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 296 $ 296''''
- Component
- Glycosylation sites (N)
- Sequence
- 296 $ 296''
Related records
Trials (14)
- A Phase 1 Study of CDX-0159
- A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects
- A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
- A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
- A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
- A Study of Barzolvolimab in Patients With Atopic Dermatitis
- A Study of Barzolvolimab in Patients With Prurigo Nodularis
- A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
- A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
- A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
- A Study of CDX-0159 in Patients With Prurigo Nodularis
- A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)
- Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
In development for (3)
- Chronic idiopathic urticaria Phase 3
- Eosinophilic esophagitis Phase 2
- Prurigo nodularis Phase 2